Brands
Zepbound and Mounjaro Are the Same Molecule. Why the Rules Differ.
Zepbound and Mounjaro both contain tirzepatide, made by the same manufacturer. They differ in approved indication — Zepbound for chronic weight management and obstructive sleep apnoea with obesity, Mounjaro for type 2 diabetes — and that difference drives everything downstream: which trials support them, how insurers treat them, and what each costs.
Key takeaways
- Both products contain tirzepatide and are made by the same manufacturer.
- Zepbound is approved for chronic weight management; Mounjaro for type 2 diabetes.
- The indication determines insurance treatment far more than the molecule does.
- Trial evidence differs: SURMOUNT supports Zepbound, SURPASS supports Mounjaro.
- Neither is interchangeable with a compounded preparation.
| Shared active ingredient | Tirzepatide |
|---|---|
| Zepbound indication | Chronic weight management; obstructive sleep apnoea with obesity |
| Mounjaro indication | Type 2 diabetes |
| Zepbound trial programme | SURMOUNT |
| Mounjaro trial programme | SURPASS |
| Dose range | 2.5 mg to 15 mg weekly for both |
If the molecule is identical, why two brands?
Because approval attaches to an indication, not to a molecule. Each indication requires its own trial programme, its own labelling, and its own regulatory submission. Marketing them separately lets the manufacturer match each to the evidence supporting it, and lets insurers apply different rules to each.
The practical consequence for patients is substantial. A plan may cover Mounjaro for diabetes and exclude Zepbound for weight management, despite the tablets — or in this case the injections — containing the same active ingredient at the same doses.
| Attribute | Zepbound | Mounjaro |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Approved indication | Chronic weight management; OSA with obesity | Type 2 diabetes |
| Pivotal programme | SURMOUNT | SURPASS |
| Typical insurance treatment | Often excluded as weight management | Usually covered as a diabetes drug |
| Self-pay channel | $299-$449 via manufacturer | Higher; figures not first-party verified here |
| Dose range | 2.5-15 mg weekly | 2.5-15 mg weekly |
Does the evidence transfer between them?
Partly, and carefully. The pharmacology is identical, so mechanism-level statements apply to both. The outcome evidence does not transfer cleanly: SURMOUNT studied weight outcomes largely in people without diabetes, while SURPASS studied glycaemic control in people with it. Weight reduction in the diabetes population is consistently smaller, which SURMOUNT-2 quantified at roughly 12.8% to 14.7% against about 20.9% without diabetes.
So quoting a Zepbound weight figure to someone with type 2 diabetes overstates what the evidence supports for them, even though the molecule is the same.
| Group | % reduction |
|---|---|
| Without diabetes (SURMOUNT-1, 15 mg) | 20.9% |
| With diabetes (SURMOUNT-2, 15 mg) | 14.7% |
| With diabetes (SURMOUNT-2, 10 mg) | 12.8% |
Which should someone ask about?
That follows from the diagnosis rather than from preference. A person with type 2 diabetes is a candidate for the diabetes indication; a person with obesity and no diabetes is not. Prescribing outside the approved indication is legal but changes coverage and is a decision for the prescriber.
What is not reasonable is choosing between them to game insurance. Coverage rules exist and the diagnosis on a claim should reflect the clinical reality.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on zepbound vs mounjaro difference.
- A change to FDA labelling or regulatory position affecting a statement above.
- A verified correction accepted through the corrections process.
- A material change to a captured price, term, or programme condition.
More from the journal: all pieces
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a qualified professional.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on zepbound and mounjaro are the same molecule. why the rules differ..
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Are Zepbound and Mounjaro the same drug?
Both contain tirzepatide from the same manufacturer. They differ in approved indication and in how insurers treat them.
Why is one covered and the other not?
Many plans cover diabetes drugs while excluding weight-management drugs, so the indication rather than the molecule drives coverage.
Can I use Mounjaro for weight loss?
That would be off-label prescribing, which is legal but changes coverage. It is a prescriber decision.
Do they cost the same?
No. Self-pay channels and coverage rules differ between the two.
Is compounded tirzepatide equivalent to either?
No. It is not FDA approved and has never been tested in a randomised trial.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.